scholarly journals PSY2 Adverse Event Burden, Resource Use and Costs Associated With Immunosuppressant Therapy for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review

2012 ◽  
Vol 15 (4) ◽  
pp. A98
Author(s):  
A. Shaul ◽  
T. Pokora ◽  
C. Paramore ◽  
L.S. Cragin ◽  
A. Weinstein ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Adverse Event ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Resource Use ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Immunosuppressant Therapy

scholarly journals Adverse Event Burden, Resource Use, and Costs Associated with Immunosuppressant Medications for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
A. Oglesby ◽  
A. J. Shaul ◽  
T. Pokora ◽  
C. Paramore ◽  
L. Cragin ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Adverse Event ◽  
Mycophenolate Mofetil ◽  
Literature Review ◽  
Adverse Events ◽  
Resource Use ◽  
Lupus Erythematosus ◽  
Treatment Options ◽  
Systemic Lupus ◽  
Immunosuppressant Medications

This paper assessed the burden of adverse events (AEs) associated with azathioprine (AZA), cyclophosphamide (CYC), mycophenolate mofetil (MMF), methotrexate (MTX), and cyclosporine (CsA) in patients with systemic lupus erythematosus (SLE). Thirty-eight publications were included. Incidence of AEs ranged from 42.8% to 97.3%. Common AEs included infections (2.4–77%), gastrointestinal AEs (3.2–66.7%), and amenorrhea and/or ovarian complications (0–71%). More hematological cytopenias were associated with AZA (14 episodes) than MMF (2 episodes). CYC was associated with more infections than MMF (40–77% versus 12.5–32%, resp.) or AZA (17–77% versus 11–29%, resp.). Rates of hospitalized infections were similar between MMF and AZA patients, but higher for those taking CYC. There were more gynecological toxicities with CYC than MMF (32–36% versus 3.6–6%, resp.) or AZA (32–71% versus 8–18%, resp.). Discontinuation rates due to AEs were 0–44.4% across these medications. In summary, the incidence of AEs associated with SLE immunosuppressants was consistently high as reported in the literature; discontinuations due to these AEs were similar across treatments. Studies on the economic impact of these AEs were sparse and warrant further study. This paper highlights the need for more treatment options with better safety profiles.

TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review

2013 ◽  
Vol 25 (4) ◽  
pp. 642-645 ◽  
Author(s):  
Marta Mosca ◽  
Chiara Tani ◽  
Maria Elena Filice ◽  
Linda Carli ◽  
Andrea Delle Sedie ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Lupus Erythematosus ◽  
Tnf Alpha ◽  
Systemic Lupus

scholarly journals The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review

Rheumatology ◽  
2015 ◽  
pp. kev343 ◽  
Author(s):  
Ahmed S. Zayat ◽  
Md Yuzaiful Md Yusof ◽  
Richard J. Wakefield ◽  
Philip G. Conaghan ◽  
Paul Emery ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Lupus Erythematosus ◽  
Musculoskeletal Symptoms ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document